← Eichor
Study identifier: NCT02817360 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

Condition: Heart Diseases · Diabetes Mellitus, Type 2  ·  Sponsor: Martin Huelsmann

PhasePhase 4
Planned participants2400
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Purpose and rationale The purpose of this study is to evaluate the effect of high dose Renin-Angiotensin System (RAS)-antagonists and beta-blocker treatment for the primary prevention of cardiac events in a population of patients with Type 2 diabetes mellitus (T2DM) with no evidence of a preexisting cardiac disease. An additional aim is to demonstrate an interaction between concentrations of amino-terminal pro-B type natriuretic peptide (NT-proBNP as a surrogate of imminent cardiac risk) and treatment effects and the economic impact of the intervention overall and in the biomarker stratified subgroups. Primary objective Superiority of high dose treatment with RAS-antagonists and beta-blockers compared to conventional therapy regarding the reduction of unplanned hospitalization or death due to a cardiac event in T2DM patients with a NT-proBNP \> 125pg/ml. There is an additional eye-substudy for Viennese sites only. The purpose of this sub-study is to evaluate the effect of high dose RAS-antagonists and beta blocker treatment on early subclinical signs of diabetic micro-angiopathy and neuropathy. An additional aim will be the evaluation of the possible impact of the cardiovascular risk factor NT-proBNP on the onset and progression of diabetic retinopathy.

This description comes directly from the study's public registry record.

Talk to the study team

Martin Huelsmann, Doz.Dr.  ·  +43 1 40400  ·  martin.huelsmann@meduniwien.ac.at

Always discuss trial participation with your own doctor first.

Locations (21)

Internistische OrdinationMödling, Lower Austria, AustriaActive Not Recruiting
Klinischen Abteilung für Endokrinologie und Diabetologie MU GrazGraz, Styria, AustriaRecruiting
Konventhospital der Barmherzigen Brüder Abteilung für Innere MedizinLinz, Upper Austria, AustriaRecruiting
Krankenanstalt Rudolfstiftung, 1. Medizinische AbteilungVienna, AustriaCompleted
Zentrum für Klinische StudienVienna, AustriaTerminated
Medical University of Vienna Univ.Clinic for Internal Medicine II Department of CardiologyVienna, AustriaRecruiting
Univ. Klinik für Innere Medizin III Med. Uni WienVienna, AustriaRecruiting
Universitätsklinik für Augenheilkunde und Optometrie Medizinische Universität WienVienna, AustriaRecruiting
Diabetes & Stoffwechselambulanz Gesundheitszentrum Wien SüdVienna, AustriaRecruiting
3. Med. Abtlg., KH Hietzing mit Neurologischem Zentrum RosenhügelVienna, AustriaTerminated
iMED19Vienna, AustriaRecruiting
Maastricht University Medical Center; Dep. CardiologyMaastricht, NetherlandsActive Not Recruiting

+ 9 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02817360